Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S1.76
P/E—
Fwd P/E15.72
PEG1.26
52W— – —
RSI—
Target$342.73 (+10.0%)
Beta0.85
Div0.94%
Loading chart…
RSI ()
Loading patterns…
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 40
Overbought · 100
Signal
Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
9Bullish
3Bearish
0Neutral
Key Signals 3
▲ Double Bottom
Major reversal
2026-06-05 · $263.93
Two lows ~$251.19 — bullish reversal confirmed
Learn more →
▲ Double Bottom
Major reversal
2026-06-29 · $275.0
Two lows ~$253.06 — bullish reversal confirmed
Learn more →
▲ Double Bottom
Major reversal
2026-07-24 · $291.38
Two lows ~$257.58 — bullish reversal confirmed
Learn more →
Momentum Signals 9
▲ MACD Bullish Crossover
▲ MACD Bullish Crossover
▲ MACD Bullish Crossover
▲ Bull Flag
View overlays on the price chart via Overview tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
100%
8/8 quarters
Wall Street Consensus
BUY
BuyHoldSell
Price Target Range
$342.73
+10.0% upside
Low $293
—
High $385
Consensus
Current price
Wall Street Analyst Ratings
Sort by
| Firm | Rating | Change | Action | Date |
|---|
Profitability
Gross Margin
28.88%Last 12 Months
Operating Margin
12.24%Last 12 Months
Return on Equity
11.73%Last 12 Months
Revenue Growth
5.80%Year over Year
Free Cash Flow
892.05MLast 12 Months
Free Cash Flow Yield
—Last 12 Months
Balance Sheet
Debt / Equity
79.12Most Recent Quarter
Current Ratio
1.80Most Recent Quarter
Cash
141.80MMost Recent Quarter
Total Debt
6.82BMost Recent Quarter
Net Debt
—Most Recent Quarter
How LH Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 25.27B |
| Enterprise Value | 31.96B |
| Trailing P/E | 25.39 |
| Forward P/E | 15.72 |
| PEG Ratio (5yr) | 1.26 |
| Price/Sales (ttm) | 1.76 |
| Price/Book (mrq) | 2.93 |
| EV/Revenue | 2.23 |
| EV/EBITDA | 13.78 |
Share Statistics
| Avg Vol (3m) | 693.12K |
| Shares Outstanding | 81.10M |
| Float | 80.72M |
| % Held by Insiders | 0.35% |
| % Held by Institutions | 101.89% |
| Short Ratio | 3.45 |
| Short % of Float | 2.60% |
Profitability
| Gross Margin | 28.88% |
| Operating Margin (ttm) | 12.24% |
| Profit Margin | 6.99% |
| Return on Assets (ttm) | 5.53% |
| Return on Equity (ttm) | 11.73% |
Income Statement
| Revenue (ttm) | 14.35B |
| Revenue Growth (yoy) | 5.80% |
| Gross Profit (ttm) | 4.14B |
| EBITDA | 2.32B |
| Net Income (ttm) | 1.00B |
| Diluted EPS (ttm) | 12.27 |
| EPS Growth (yoy) | 28.20% |
Balance Sheet
| Total Cash (mrq) | 141.80M |
| Total Debt (mrq) | 6.82B |
| Debt / Equity (mrq) | 79.12 |
| Current Ratio (mrq) | 1.80 |
| Book Value / Share | 106.39 |
| Operating CF (ttm) | 1.64B |
| Free Cash Flow (ttm) | 892.05M |
Trading & Dividends
| Beta (5Y) | 0.85 |
| 50-Day MA | 308.97 |
| 200-Day MA | 276.43 |
| Fwd Dividend Yield | 0.94% |
| Payout Ratio | 23.82% |
Income
Dividend Yield
0.94%Last 12 Months
Annual Rate
2.88Forward
Payout Ratio
23.82%Last 12 Months
Dividend History
Payout Ratio (Last 12 Months): 23.82%
Monthly Dividends
Ownership Breakdown
Institutional 101.89%
Insider 0.35%
Short Interest
2.60% of float
Low
Institutional 13F Holdings
Famous investors who disclosed a position in LH in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Price | Value |
|---|